Search Results

You are looking at 201 - 210 of 2,881 items for :

  • Refine by Access: All x
Clear All
Full access

Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy

Douglas W. Blayney, Nicole M. Kuderer, Alice Kate Cummings Joyner, John Jarvis, Dominic Nunag, Jasmine Wells, Lan Huang, Ramon Mohanlal, and Gary H. Lyman

immediately preceding the index date, and included patient demographics, comorbidities, and healthcare resource utilization. To investigate the real-world protective benefit of PP G-CSFs, proportions of patients experiencing the primary outcome of FN or

Full access

EHR-Integrated Patient-Reported Outcomes in Ambulatory Oncology: A Critical Opportunity for Timely and Targeted Palliative Care

Patricia I. Moreno, Frank J. Penedo, Felicia M. Knaul, Carina Oltmann, Michael T. Huber, and Mariana Khawand-Azoulai

The aim of systematic symptom screening and monitoring using patient-reported outcomes (PROs) is to collect actionable data and provide responsive care that is centered around patients’ needs. Recent evidence demonstrates that routine assessment

Full access

Letter to the Editor: Integrating Skeletal Muscle Mass and Radiodensity Improves Outcome Prediction and Correlation in Oncologic Studies

Grant R. Williams, Marc S. Weinberg, and Shlomit S. Shachar

dichotomizing participants as high or low radiodensity, why not integrate these 2 variables into 1 continuous variable? Because both muscle mass and radiodensity are defined independently and both are prognostic of many adverse cancer outcomes, we have proposed

Full access

CLO21-029: Impact of Comorbidity Patterns on the Outcomes of Older Patients With Diffuse Large B- Cell Lymphoma

Karen Valdés-Díaz, Halbert Hernández-Negrín, Leonel Valdés-Leiva, Diana Martin-Oliva, and Dianelys Pedraza-González

Background: Comorbidity in elderly has made it difficult to manage when they are affected by aggressive non-Hodgkin's lymphoma. This has led to the historical achievement of poor outcomes, hence the analysis of the impact of comorbidity in this

Full access

QIM20-121: Oncology Nursing Evidenced Practice and Research Committee; Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines

Kristen Burns, Archana Shenoy, and Nicole Turkoglu

population, examine policy and nursing practices to better navigate patients through the continuum of oncology care and improve patient outcomes. The purpose is to describe how the formation of an evidence-based practice committee can engage specialized

Full access

CLO22-060: > 3 Courses of Neo-Adjuvant Chemotherapy (NACT) May Affect Outcomes of Advanced Ovarian Serous Adenocarcinoma Patients

Yunyun Liu, KKL Chan, and Hui Zhou

relapse, indicating that the poorer outcome of patients with NACT>3 may not be caused by chemo-induced resistance. The reason of worse outcomes after more cycles of NACT is still needed to be explored. CLO22-060 Figure 1 CLO22-060 Table 1

Full access

HSR20-091: Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia

Stephenie Kennedy-Rea, Adrienne Duckworth, Amy Reasinger Allen, and Samaneh Kalirai

decrease the consequences of treatment. In this analysis, we summarize the program outcomes and provide an economic perspective on implementation and sustainability. The Bridge Program enrolls and assesses patients at the end of cancer treatment using a

Full access

The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids

Neil J. Shah, Michael R. Cook, Tianmin Wu, Shaked Lev-Ari, Matthew J. Blackburn, Michael T. Serzan, Adil Alaoui, Jaeil Ahn, and Michael B. Atkins

equivalent for >4 weeks receive antimicrobial prophylaxis for Pneumocystis jirovecii pneumonia (PJP). Limited data exist regarding the incidence and outcome of OIs among patients receiving ICIs who need SS and/or ISAs for >4 weeks to manage irAEs

Full access

The Management of Patients With Stage IIIA Non–Small Cell Lung Cancer With N2 Mediastinal Node Involvement

Renato G. Martins, Thomas A. D’Amico, Billy W. Loo Jr, Mary Pinder-Schenck, Hossein Borghaei, Jamie E. Chaft, Apar Kishor P. Ganti, Feng-Ming (Spring) Kong, Mark G. Kris, Inga T. Lennes, and Douglas E. Wood

scan. Outcomes would be expected to differ significantly between these groups. Andre et al. 5 retrospectively analyzed data on 702 consecutive patients with N2 disease at 6 French centers and found that the degree of N2 involvement correlated with

Full access

Predictive Biomarkers for Anti-Epidermal Growth Factor Receptor Therapy: Beyond KRAS Testing

Noman Ashraf, Nishi Kothari, and Richard Kim

agents and targeted therapies against both vascular endothelial growth factor and epidermal growth factor receptor (EGFR), survival has improved. However, outcomes remain highly variable because CRC is a heterogeneous multipathway disease. 2 , 3 It is